Sobi Releases Q2 2025 Financial Report
Swedish Orphan Biovitrum AB (publ) (Sobi) has announced its second-quarter financial results for 2025, highlighting considerable growth in both its revenue and strategic portfolio. The report reflects Sobi's commitment to providing innovative therapies for patients with rare diseases, while also demonstrating the strength of its expanding product pipeline.
Q2 2025 Financial Highlights
In the recently published financial report, Sobi revealed that total revenue rose by an impressive 13% year-on-year, with an even more significant 22% increase when considering constant exchange rates. This translates to SEK 6,175 million, demonstrating the company’s robust financial health.
Haematology Revenue Surge
Haematology sales drove much of this growth, surging by 27% at constant exchange rates to SEK 4,570 million. The impressive figures were largely underpinned by the successful launch of Altuvoct, which alone contributed SEK 627 million. Additionally, sales from Doptelet reached SEK 1,220 million, complemented by significant contributions from Aspaveli/Empaveli, which generated SEK 304 million. Although sales of Vonjo saw a slight decline, the overall performance in the haematology segment remained strong.
Immunology Sector Performance
In the immunology space, Sobi's revenue grew by 11% at constant exchange rates, totaling SEK 1,288 million. Strong sales from Gamifant contributed SEK 632 million, while Kineret sales increased to SEK 749 million, showcasing the continued demand for Sobi's innovative treatments in this crucial area.
Strategic Portfolio Growth
The performance of Sobi’s strategic portfolio was particularly noteworthy, with revenue climbing by an impressive 65% at constant exchange rates. Totaling SEK 3,384 million, this reflects Sobi's successful strategy of integrating new therapies into their offerings.
Profitability and Earnings Summary
Sobi’s adjusted EBITA margin for the quarter stood at a solid 34%, up from 28% in the prior year. The EBITA was SEK 1,863 million, equating to a margin of 30% compared to 27% in the prior year. Reported EBIT reached SEK 1,010 million, signaling a strong trajectory towards enhanced profitability.
Earnings Per Share Analysis
For Q2 2025, earnings per share (EPS) before dilution was SEK 1.85, significantly improved from SEK 0.66 in the same quarter of the previous year. The diluted EPS mirrored this trend, demonstrating solid earnings growth amidst increasing revenues.
Cash Flow Assessment
Cash flow from operating activities recorded SEK 1,448 million, although this figure reflects a decline compared to the previous year. This highlights Sobi's focus on managing its resources effectively while investing in future growth opportunities.
Looking Ahead: 2025 Outlook
As Sobi looks towards the future, the company maintains its guidance for a high single-digit percentage revenue growth at constant exchange rates. The adjusted EBITA margin is also expected to remain stable in the mid-30s percentage of revenue, fostering confidence among investors.
Investor Conference Call
On the same day as the report release, Sobi invited investors, analysts, and the media to a conference call at 14:00 CEST, which included a discussion of the results and a Q&A session. This open dialogue underscores Sobi's commitment to transparency and engagement with its stakeholder community.
About Sobi
Sobi is a global biopharma company that focuses on breakthrough innovations aimed at transforming the lives of individuals with rare diseases. With around 1,900 employees spread across different continents, the company reported revenue of SEK 26 billion in the past year. Its shares are listed on Nasdaq Stockholm under the ticker symbol STO: SOBI, reflecting its standing in the market while enhancing shareholder value.
Frequently Asked Questions
What financial performance did Sobi report for Q2 2025?
Sobi reported a total revenue increase of 13% year-on-year for Q2 2025, reaching SEK 6,175 million.
How did Sobi's haematology revenue perform?
Haematology revenue saw a significant increase of 27% at constant exchange rates, totaling SEK 4,570 million.
What is the outlook for Sobi in 2025?
Sobi anticipates a high single-digit percentage revenue growth at constant exchange rates and expects the adjusted EBITA margin to remain in the mid-30s percentage of revenue.
When was the investor conference call scheduled?
The investor conference call was held on the same day as the financial report release at 14:00 CEST.
Where can I find more information about Sobi?
More information can be found on Sobi's official website, where they provide details about their products, corporate initiatives, and investor relations.
